<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046500</url>
  </required_header>
  <id_info>
    <org_study_id>INOMEN-2010</org_study_id>
    <nct_id>NCT01046500</nct_id>
  </id_info>
  <brief_title>Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of
      living cells and is widespread in many food. It is involved in a number of biological
      processes, including insulin signal transduction, resulting in modulating insulin
      sensitivity. One hundred post-menopausal women from 50 to 60 years old, affected by metabolic
      syndrome (criteria are described in NIH ATP III) will be randomized into two groups: 50
      treated with myo-inositol 2 g twice per day and fifty treated with metformin for six months.
      Metformin is the drug usually used in diabetic and pre-diabetic conditions, as metabolic
      syndrome. The investigators hypothesize that the administration of myo-inositol would improve
      the insulin-receptor activity in these women, reducing insulin resistance as well as
      metformin.

      OUTCOME MEASURE: HOMA-IR, blood pressure level, serum triglycerides and cholesterol, BMI and
      waist circumference
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycaemia, insulinaemia, HOMA-IR</measure>
    <time_frame>at baseline and after 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum triglycerides, HDL and total cholesterol, blood pressure level, BMI and waist circumference</measure>
    <time_frame>at baseline and after six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>myo-inositol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>myo-inositol</intervention_name>
    <description>2 grams twice a day</description>
    <arm_group_label>myo-inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>pill, 250 mg, twice a day</description>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal outpatients affected by the metabolic syndrome, whose criteria are
             described in NIH ATP III, 2001.

        Exclusion Criteria:

          -  Post-menopausal outpatients without metabolic syndrome

          -  assumption of hypocholesterolemic or other insulin sensitizing drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario D'Anna, associate professor</last_name>
      <phone>+39 090 2217324</phone>
      <email>rosariodanna@tin.it</email>
    </contact>
    <investigator>
      <last_name>Rosario D'Anna, associate professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Rosario D'anna</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>body mass index</keyword>
  <keyword>myo-inositol</keyword>
  <keyword>serum triglycerides and cholesterol</keyword>
  <keyword>blood pressure</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

